[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Myriad Genetics Inc (MYGN)

Myriad Genetics Inc (MYGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Myriad Genetics Inc 322 NORTH 2200 WEST SALT LAKE CITY UT 84116 USA

www.myriad.com Employees: 2,700 P: 801-584-3600 F: 801-584-3640

Sector:

Medical

Description:

Myriad Genetics employs a number of proprietary technologies to target the genetic basis of human diseases and the role these genes might play in the onset, progression and treatment of the respective diseases. The company has more than 10 proprietary molecular diagnostic products in market. It has made significant progress in transition & expand the hereditary cancer market, diversify revenues by commercializing its new products, increase the company's international contribution by investing in large countries, gaining reimbursement for new products, increasing international RNA kit revenue and enhancing profitability. Its flagship product BRACAnalysis offers a comprehensive analysis of BRCA1 and BRCA2 genes to assess a woman's risk of hereditary breast and ovarian cancers. Its major products are myRisk Hereditary Cancer, myPlan Lung Cancer and molecular diagnostic test myPath Melanoma. It acquired Counsyl, Inc. The company has 2 operating units: Molecular diagnostic & Pharmaceutical and clinical services.

Key Statistics

Overview:

Market Capitalization, $K 397,626
Enterprise Value, $K 367,926
Shares Outstanding, K 94,448
Float, K 92,653
% Float 98.10%
Short Interest, K 8,240
Short Float 8.72%
Days to Cover 7.92
Short Volume Ratio 0.43
% of Insider Shareholders 1.90%
% of Institutional Shareholders 99.02%

Financials:

Annual Sales, $ 824,500 K
Annual Net Income, $ -365,900 K
Last Quarter Sales, $ 200,400 K
Last Quarter Net Income, $ -34,100 K
EBIT, $ -64,100 K
EBITDA, $ 309,000 K

Growth:

1-Year Return -4.24%
3-Year Return -78.98%
5-Year Return -85.22%
5-Year Revenue Growth 433.31%
5-Year Earnings Growth 31.43%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.09 on 05/05/26
Next Earnings Date 08/04/26
Earnings Per Share ttm -0.33
EPS Growth vs. Prev Qtr -900.00%
EPS Growth vs. Prev Year -14.29%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Most Recent Dividend 1.750 on 06/15/09
Dividend Payout Ratio 0.00%
Most Recent Split 2-1 on 03/26/09

MYGN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -8.51%
Return-on-Assets % -4.48%
Profit Margin % -44.38%
Debt/Equity 0.36
Price/Sales 0.49
Price/Cash Flow 1.14
Price/Book 1.20
Book Value/Share 3.57
Interest Coverage -36.63
60-Month Beta 1.81
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.